1256390-26-7

Basic information

• Product Name: methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate
• Synonyms: methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate
• CAS NO: 1256390-26-7
• Molecular Weight: 507.384
• Mol File: 1256390-26-7.mol
• Article Data: 10

Chemical Properties

• CAS DataBase Reference: methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate(CAS DataBase Reference)
• NIST Chemistry Reference: methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate(1256390-26-7)
• EPA Substance Registry System: methyl ((S)-1-((S)-8-(5-(4-bromophenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)-3-methyl-1-oxobutan-2-yl)carbamate(1256390-26-7)

Safety Data

• Hazardous Substances Data: 1256390-26-7(Hazardous Substances Data)

Upstream product

• 1256390-39-2 (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid 2-(4-bromo-phenyl)-2-oxo-ethyl ester 
• 1256390-38-1 (S)-7-((S)-2-((methoxycarbonyl)amino)-3-methylbutanoyl)-1,4-dioxa-7-azaspiro[4.4]nonane-8-carboxylic acid 
• 1272654-95-1 (S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]nonane-8-carboxylic acid methyl ester 
• 1272654-92-8 (S)-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-4-oxo-pyrrolidine-2-carboxylic acid methyl ester 
• 1272654-89-3 (2S,4R)-4-Hydroxy-1-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-pyrrolidine-2-carboxylic acid methyl ester 
• 111398-44-8 N-methoxycarbonyl-L-valine 
• 72-18-4 L-valine 
• 16217-17-7 7-<(phenylmethoxy)carbonyl>-1,4-dioxa-7-azaspiro<4,4>-nonane-8(S)-carboxylic acid methyl ester 
• 16217-15-5 1-benzyloxycarbonyl-4-oxo-L-proline methyl ester 
• 57653-35-7 (2S,4S)-4-hydroxypyrrolidine-1,2-dicarboxylic acid 1-benzyl 2-methyl 
• 618-27-9 hydroxy L-proline 
• 40216-83-9 L-4-hydroxyproline methyl ester hydrochloride 

Downstream Products

• 1433280-22-8 4'-{2-[(S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]non-8-yl]-1H-imidazol-4-yl}-biphenyl-4-carboxylic acid 
• 1433280-02-4 (4'-{2-[(S)-7-((S)-2-methoxycarbonylamino-3-methyl-butyryl)-1,4-dioxa-7-aza-spiro[4.4]non-8-yl]-1H-imidazol-4-yl}-2-trifluoromethoxy-biphenyl-4-yl)-carbamic acid tert-butyl ester 
• 1399843-64-1 methyl ((S)-3-methyl-1-oxo-1-((S)-8-(5-(4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)phenyl)-1H-imidazol-2-yl)-1,4-dioxa-7-azaspiro[4.4]nonan-7-yl)butan-2-yl)carbamate 

Relevant articles and documents

As hepatitis c inhibitor spiro compound and its use in medicine

The invention provides a spiro compound serving as a hepatitis c inhibitor and application thereof in a medicine. The compound is a compound as shown in a formula (I) or a stereisomer, a geometric isomer, a tautomer, nitric oxide, an aquo-complex, a solvate, a metabolite, pharmaceutically acceptable salt or prodrug of the compound as shown in the formula (I). The invention also provides a pharmaceutical composition containing the compound, application of the compound and the pharmaceutical composition in inhibition of HCV (Hepatitis C Virus) copy and HCV virus protein, as well as the application of the compound and the pharmaceutical composition in prevention, handling, treatment or relieving of HCV infection or hepatitis c disease for a patient. The formula I is as shown in the specification.

Bridged Ring compounds As Hepatitis C Virus (HCV) Inhibitors And Pharmaceutical Applications Thereof

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.

BRIDGED RING COMPOUNDS AS HEPATITIS C VIRUS (HCV) INHIBITORS AND PHARMACEUTICAL APPLICATIONS THEREOF

Provided herein is a compound having Formula (I), or a stereoisomer, a geometric isomer, a tautomer, an N-oxide, a hydrate, a solvate, a metabolite, a pharmaceutically acceptable salt or a prodrug thereof, which can be used for treating HCV infection or a HCV disorder. Also provided herein are pharmaceutical compositions comprising the compounds disclosed herein, which can be used for treating HCV infection or a HCV disorder.